Cell MedX Corp. (CMXC)
USD 0.43
(0.0%)
USD 0.43
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 872.57 Thousand USD | -64.94% |
| 2023 | 2.48 Million USD | 21.38% |
| 2022 | 2.05 Million USD | 25.92% |
| 2021 | 1.62 Million USD | -3.05% |
| 2020 | 1.67 Million USD | -14.45% |
| 2019 | 1.96 Million USD | 75.48% |
| 2018 | 1.11 Million USD | -23.54% |
| 2017 | 1.46 Million USD | -12.99% |
| 2016 | 1.68 Million USD | 130.14% |
| 2015 | 730.63 Thousand USD | 3283.17% |
| 2014 | 21.59 Thousand USD | 68.1% |
| 2013 | 12.84 Thousand USD | 0.0% |
| 2012 | 12.84 Thousand USD | 278.97% |
| 2011 | 3390.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.53 Million USD | 1.81% |
| 2024 FY | 872.57 Thousand USD | -64.94% |
| 2024 Q4 | 872.57 Thousand USD | 10.19% |
| 2024 Q3 | 791.86 Thousand USD | -68.93% |
| 2024 Q2 | 2.54 Million USD | 0.58% |
| 2023 Q2 | 2.22 Million USD | 4.22% |
| 2023 Q3 | 2.31 Million USD | 4.28% |
| 2023 Q1 | 2.13 Million USD | 4.04% |
| 2023 FY | 2.48 Million USD | 21.38% |
| 2023 Q4 | 2.48 Million USD | 7.34% |
| 2022 Q3 | 1.89 Million USD | 6.38% |
| 2022 Q1 | 1.65 Million USD | 1.7% |
| 2022 Q2 | 1.78 Million USD | 7.56% |
| 2022 FY | 2.05 Million USD | 25.92% |
| 2022 Q4 | 2.05 Million USD | 8.22% |
| 2021 Q3 | 1.98 Million USD | 11.68% |
| 2021 FY | 1.62 Million USD | -3.05% |
| 2021 Q4 | 1.62 Million USD | -18.16% |
| 2021 Q1 | 1.72 Million USD | 2.75% |
| 2021 Q2 | 1.78 Million USD | 3.23% |
| 2020 Q2 | 1.87 Million USD | 15.83% |
| 2020 FY | 1.67 Million USD | -14.45% |
| 2020 Q1 | 1.61 Million USD | -17.73% |
| 2020 Q3 | 1.69 Million USD | -9.59% |
| 2020 Q4 | 1.67 Million USD | -0.7% |
| 2019 Q4 | 1.96 Million USD | 5.52% |
| 2019 Q1 | 1.36 Million USD | 22.29% |
| 2019 Q2 | 1.53 Million USD | 12.0% |
| 2019 FY | 1.96 Million USD | 75.48% |
| 2019 Q3 | 1.86 Million USD | 21.42% |
| 2018 Q3 | 1 Million USD | 2.01% |
| 2018 Q1 | 1.56 Million USD | 6.85% |
| 2018 FY | 1.11 Million USD | -23.54% |
| 2018 Q4 | 1.11 Million USD | 11.72% |
| 2018 Q2 | 981.62 Thousand USD | -37.21% |
| 2017 FY | 1.46 Million USD | -12.99% |
| 2017 Q1 | 1.89 Million USD | 12.69% |
| 2017 Q2 | 880.32 Thousand USD | -53.54% |
| 2017 Q3 | 1.1 Million USD | 25.72% |
| 2017 Q4 | 1.46 Million USD | 32.2% |
| 2016 Q1 | 943.33 Thousand USD | 29.11% |
| 2016 FY | 1.68 Million USD | 130.14% |
| 2016 Q4 | 1.68 Million USD | 22.99% |
| 2016 Q3 | 1.36 Million USD | 22.63% |
| 2016 Q2 | 1.11 Million USD | 18.19% |
| 2015 Q2 | 393.36 Thousand USD | 439.06% |
| 2015 Q1 | 72.97 Thousand USD | 237.9% |
| 2015 Q4 | 730.63 Thousand USD | 26.07% |
| 2015 FY | 730.63 Thousand USD | 3283.17% |
| 2015 Q3 | 579.54 Thousand USD | 47.33% |
| 2014 Q4 | 21.59 Thousand USD | 33.27% |
| 2014 Q3 | 16.2 Thousand USD | 25.57% |
| 2014 Q2 | 12.9 Thousand USD | -1.54% |
| 2014 Q1 | 13.1 Thousand USD | 2.02% |
| 2014 FY | 21.59 Thousand USD | 68.1% |
| 2013 Q4 | 12.84 Thousand USD | -0.77% |
| 2013 FY | 12.84 Thousand USD | 0.0% |
| 2013 Q2 | 12.94 Thousand USD | 0.78% |
| 2013 Q1 | 12.84 Thousand USD | 0.0% |
| 2013 Q3 | 12.94 Thousand USD | 0.0% |
| 2012 Q4 | 12.84 Thousand USD | -24.23% |
| 2012 Q3 | 16.95 Thousand USD | 31.98% |
| 2012 FY | 12.84 Thousand USD | 278.97% |
| 2012 Q1 | 6965.00 USD | 105.46% |
| 2012 Q2 | 12.84 Thousand USD | 84.45% |
| 2011 Q4 | 3390.00 USD | 0.0% |
| 2011 FY | 3390.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| RetinalGenix Technologies Inc. | 1.4 Million USD | 37.931% |